Introduction

Wounds are a major threat to public health and the economy. The cost of wounds to the US healthcare system annually is measured in billions of dollars. According to the National Institutes of Health (NIH), the treatment of chronic wounds alone exceeds an estimated $25 billion each year. Acute and emergency wound care related to trauma, surgery and burns is required for millions of procedures.

The purpose of this white paper is to introduce a product manufactured with patented biotechnology that will lead the next generation of wound care treatment and healing. SilvrSTAT® Antibacterial Wound Dressing Gel is a molecular silver product nanoengineered to provide superior wound management more effectively than any other product on the market.

Full text

Read the full text of The Next Generation of Wound Care: A White Paper on SilvrSTAT Antibacterial Wound Dressing Gel, originally published in Wound Care Therapies, Spring 2014. Published with permission of ABL Medical, makers of SilvrSTAT.